Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks reports.
Several other brokerages also recently commented on ELVN. Stifel Nicolaus lifted their target price on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. JPMorgan Chase & Co. started coverage on Enliven Therapeutics in a research note on Thursday, October 1st. They issued an “overweight” rating and a $75.00 target price on the stock. William Blair initiated coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating for the company. Morgan Stanley began coverage on shares of Enliven Therapeutics in a report on Friday, October 2nd. They issued an “overweight” rating and a $70.00 price target on the stock. Finally, Mizuho upped their price objective on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a report on Tuesday, August 18th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Enliven Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $75.44.
Read Our Latest Stock Analysis on ELVN
Enliven Therapeutics Stock Down 5.6%
Shares of Enliven Therapeutics stock opened at $48.31 on Wednesday. The business’s 50 day simple moving average is $46.65 and its two-hundred day simple moving average is $43.56. Enliven Therapeutics has a one year low of $14.78 and a one year high of $62.32.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.09. On average, research analysts predict that Enliven Therapeutics will post -1.70 EPS for the current fiscal year.
Insider Activity at Enliven Therapeutics
In related news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $38.48, for a total transaction of $231,572.64. Following the completion of the transaction, the chief financial officer owned 38,000 shares of the company’s stock, valued at $1,462,240. This trade represents a 13.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $46.67, for a total value of $606,710.00. Following the transaction, the director owned 13,000 shares of the company’s stock, valued at $606,710. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 31,054 shares of company stock worth $1,493,823 in the last 90 days. 3.00% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Enliven Therapeutics
A number of institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its position in shares of Enliven Therapeutics by 70.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 681,715 shares of the company’s stock worth $26,714,000 after purchasing an additional 282,822 shares during the last quarter. Legal & General Group Plc bought a new position in Enliven Therapeutics in the 2nd quarter worth about $1,671,000. Nicholas Investment Partners LP bought a new position in Enliven Therapeutics in the 2nd quarter worth about $19,870,000. Avidity Partners Management LP grew its position in Enliven Therapeutics by 185.1% during the 1st quarter. Avidity Partners Management LP now owns 400,000 shares of the company’s stock valued at $15,680,000 after purchasing an additional 259,700 shares during the last quarter. Finally, Handelsbanken Fonder AB purchased a new stake in Enliven Therapeutics during the 2nd quarter valued at about $878,000. 95.08% of the stock is owned by hedge funds and other institutional investors.
Enliven Therapeutics Company Profile
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth. The company’s pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2. Enliven is based in Boulder, Colorado.
Further Reading
- Five stocks we like better than Enliven Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
